Drug Profile

Denosumab biosimilar - Prestige Biopharma

Alternative Names: PBP 1601

Latest Information Update: 30 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Prestige BioPharma
Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
Mechanism of Action Antibody-dependent cell cytotoxicity; RANK ligand inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

24 Jul 2024 Discontinued - Phase-I for Osteoporosis in Singapore (Parenteral) before July 2024 (Prestige BioPharma pipeline, July 2024)
24 Jul 2024 Preclinical trials in Endocrine disorders in Singapore (Parenteral) before July 2024 (Prestige BioPharma pipeline, July 2024)
28 Jan 2024 No recent reports of development identified for phase-I development in Osteoporosis in Singapore (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com